A non-invasive blood test to support the early assessment of Alzheimer’s disease.

LucentAD pTau217™ is a pioneering Alzheimer’s blood test designed to provide clearer insight when memory or cognitive symptoms raise concern. By analysing p-Tau 217, a key biomarker strongly associated with Alzheimer’s disease, this test helps clinicians determine whether Alzheimer’s pathology is likely to be present — without the need for invasive or expensive procedures. For many people, traditional Alzheimer’s diagnosis can involve long waiting lists, lumbar punctures, or PET scans. LucentAD pTau217™ offers a faster, simpler, and more accessible alternative, delivering clinically meaningful results in 70% of patients.

What is p-Tau 217?

p-Tau 217 is one of the most specific blood biomarkers linked to Alzheimer’s disease. Elevated levels are strongly associated with the presence of Alzheimer’s pathology, making it a powerful tool in modern dementia assessment.

LucentAD pTau217™ measures this biomarker using a simple blood sample, helping healthcare professionals rule in or rule out Alzheimer’s disease with a high degree of confidence.

Why Choose an Alzheimer’s Blood Test?

Blood-based biomarkers are transforming how Alzheimer’s disease is assessed. LucentAD pTau217™ brings cutting-edge science into a simple, accessible format — helping reduce uncertainty, delays, and unnecessary invasive testing.

Important Information. LucentAD pTau217™ is intended to support clinical assessment and should always be interpreted by a qualified healthcare professional. It does not replace a full clinical evaluation or medical diagnosis.

Ready to take the next step?

Order the LucentAD pTau217™ Alzheimer’s blood test today and gain clearer insight — sooner.